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Abstract HERC1 is a very large protein involved in membrane
tra⁄c through both its ability to bind clathrin and its guanine
nucleotide exchange factor (GEF) activity over ARF and Rab
family GTPases. Herein, we show that HERC1 is recruited
onto actin-rich surface protrusions in ARF6-transfected HeLa
cells upon aluminum £uoride (AlF34 ) treatment. Moreover, the
fact that HERC1 overexpression does not stimulate protrusion
formation in the absence of AlF34 , in conditions where ARNO
does, indicates that HERC1 is not acting as an ARF6-GEF in
this system, but that instead its recruitment takes place down-
stream of ARF6 activation. Finally, we suggest a phosphoinosi-
tide-binding mechanism whereby HERC1 may translocate to
these protrusions.
/ 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The human proteome contains four HERC proteins [1^8],
which are characterized by possessing both HECT and RCC1-
like (RLD) domains. While the former are widely assumed to
confer E3 ubiquitin ligase activity to proteins containing them
[9,10], the latter have been suggested to act as guanine nucle-
otide exchange factors (GEFs) for small GTP-binding pro-
teins [1,11]. HERC1, the largest family member (532 kDa),
was the ¢rst to be identi¢ed and so far it has been the most
extensively studied [1^4]. Its long amino acid sequence (4861
amino acid residues) contains a number of conserved regions.
Among them, the most remarkable are the C-terminal HECT
domain, the two RLDs (RLD1 and RLD2), three putative
SH3-binding sites, a SPRY domain, a WD-40 domain and
an F-box motif [3]. The protein seems to be ubiquitously ex-
pressed, with higher levels in brain and testis, and it is over-
expressed in tumor cell lines compared to normal ones [1].
Concerning its subcellular distribution, HERC1 is located in
both the cytosol and inner cell membranes, the Golgi appa-
ratus among them [1]. Although it has not yet been proven in
vivo, the in vitro observations that HERC1 can bind to
(through its RLD2) and stimulate (via its RLD1) guanine
nucleotide dissociation from ARF1, a small GTPase control-
ling vesicle coat recruitment in the Golgi, may indicate that
HERC1 has an important function in the regulation of mem-
brane tra⁄c in this organelle [1]. Likewise, the ability of
HERC1’s RLD1 domain to dissociate guanine nucleotides
from Rab3a and Rab5 active sites might argue for a role of
HERC1 in exo- and endocytosis, respectively [1]. On the other
hand, HERC1 has also been shown to form in vivo a cytosolic
ternary complex with clathrin heavy chain (CHC) and the
chaperone Hsp70, the latter dissociating from it when ATP
is present [2]. The interaction between HERC1 and CHC
takes place between HERC1’s RLD2 and a region in CHC
(amino acids 1315^1557) which encompasses the clathrin light
chain-binding site [2], thus prompting the suggestion that
HERC1 might somehow control clathrin coat assembly on
the surface of vesicles. Finally, recent ¢ndings show an inter-
action between HERC1, through its HECT domain, and gly-
colytic isoenzyme M2-type pyruvate kinase. Nevertheless, the
physiological signi¢cance of this interaction could not be pin-
pointed [3]. Taken together, these data generate a rough pic-
ture of HERC1 as a regulator of membrane tra⁄c potentially
through three di¡erent mechanisms: GEF activity over ARF
and Rab family GTPases, binding to CHC and ubiquitination
of target proteins.
Cortical actin cytoskeleton rearrangements have been impli-
cated in several important cellular functions such as phagocy-
tosis and cell motility [12,13]. Although these actin rearrange-
ments are in most cases orchestrated by members of the Rho
family of GTPases [14], ARF6, a member of the ADP-ribo-
sylation factor family, has also been shown to play an impor-
tant role in their regulation. In particular, experiments carried
out in HeLa cells have demonstrated that an increase in the
level of ARF6 activation leads to enhanced actin polymeriza-
tion at the cell surface and to formation of actin-based mem-
brane protrusions which are di¡erent from the actin structures
formed upon activation of Rho family members [15,16]. A
number of empirical approaches have been developed in order
to elevate the activity of cellular ARF6. These include trans-
fection of constitutively active or fast cycling mutants of
ARF6 [17,18], overexpression of ARF6-GEFs such as ARNO
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or EFA6 [19,20] and use of the heterotrimeric G protein acti-
vator aluminum £uoride (AlF34 ), which needs to be combined
with wild type ARF6 overexpression in order to cause its
e¡ects [15]. This drug appears to act in HeLa cells by target-
ing the K subunit of heterotrimeric Gq. In agreement with
these data, a constitutively active mutant of GKq has been
reported to induce protrusions in the absence of AlF34 [21].
In any case, it is well established that AlF34 exerts its e¡ects
upon the cortical actin cytoskeleton speci¢cally through
ARF6 activation. This is most obvious from the observation
that treatments causing ARF6 to undergo inactivation (trans-
fection of dominant-negative or non-myristoylatable mutants
of ARF6 [15] or overexpression of ARF6-GTPase activating
proteins such as PAG3 or ACAP1 [22,23]) totally block pro-
trusion formation in response to AlF34 . The same outcome
can be achieved by transfection of an e¡ector domain mutant
of ARF6 likewise incapable of sustaining protrusion forma-
tion [21]. Aside from the essential involvement of ARF6, rel-
atively little is known about which physiological stimuli acti-
vate ARF6 [15,24] and which are the ARF6 e¡ectors.
Concerning this last aspect, however, it has recently been
shown that one of the most important mechanisms whereby
active ARF6 may give rise to protrusions is by its ability to
stimulate phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2)
synthesis [25^29]. Indeed, this phospholipid is highly enriched
in protrusive membranes [29] and it is likely to act as an
anchor for other proteins involved in protrusion dynamics.
In this study, we show that HERC1 is recruited onto actin-
rich surface protrusions formed in ARF6-transfected HeLa
cells upon AlF34 treatment. We also show that HERC1 re-
cruitment to these structures occurs downstream of ARF6
activation. Moreover, we demonstrate an interaction between
HERC1’s RLD1 domain and phosphoinositides, which we
suggest may be the underlying mechanism whereby HERC1
translocates to protrusive membranes. Finally, we speculate
on the function HERC1 may ful¢ll in such structures.
2. Materials and methods
2.1. Reagents and antibodies
AlF34 was prepared from AlCl3 (Sigma) and NaF (Merck). Azolec-
tin (soybean phosphatidylcholine type II-S) and PI(4,5)P2 were both
from Sigma. PIP strips were purchased from Echelon Biosciences (Salt
Lake City, UT, USA). Phalloidin-£uorescein isothiocyanate (FITC)
and phalloidin-Texas red isothiocyanate (TRITC) (Sigma) were used
at 0.1 Wg/ml. Goat anti-mouse or anti-rabbit F(abP)2 fragments con-
jugated to either Alexa Fluor 488 or Alexa Fluor 568 were purchased
from Molecular Probes and used at 0.5 Wg/ml. Mouse monoclonal
antibodies against hemagglutinin (clone HA-7), Flag (clone M2) and
Myc (clone 9E10) epitopes were all from Sigma. A⁄nity-puri¢ed rab-
bit polyclonal antibodies against HERC1 (410) have already been
described [1].
2.2. Plasmids
pJLR155 was obtained by introducing the 15 kb EcoRI insert from
plasmid pFG3 [3] into vector pEGFP-C2 (BD Biosciences). pJLR130
was constructed by ligating into pET21c (Novagen) the 1.4 kb Bam-
HI-NotI insert from pJLR16 (pVL1393-His-RLD2) [1]. Analogously,
pJLR131 was created by inserting into pET21c the 1.4 kb fragment
resulting from pJLR73 (pBlueBac-His-RLD1) [1] digestion with Bam-
HI and EcoRI. pARNO-Myc, pPH-phospholipase CN1 (PLCN1)-green
£uorescent protein (GFP) and pMyc-PI(4)P-5KK were supplied by
Dr. James E. Casanova [19], Dr. Tamas Balla [30] and Dr. Michael
A. Frohman [25], respectively, while pARF1-HA, pARF6-HA,
pARF6-T27N-HA and pARF6-Q67L-HA were a gift from Dr. Julie
G. Donaldson [15].
2.3. Protein puri¢cation, pull-downs and lipid^protein overlay assays
RLD1- and RLD2-Flag were puri¢ed by a⁄nity chromatography
from Escherichia coli BL21 cells transformed with plasmids pJLR131
or pJLR130, respectively. These puri¢cations were carried out basi-
cally as described in [1]. Liposome^protein complex formation assays
were basically carried out as reported in [31]. Brie£y, 0.5 Wg of RLD1-
Flag or RLD2-Flag were added to 100 Wl of lipid vesicles (1 mg/ml)
prepared from either azolectin alone or the same amount of azolectin
plus 100 WM PI(4,5)P2 incorporated through co-sonication. The mix-
ture was then incubated for 5 min before ultracentrifugation at
100 000Ug for 30 min. The pelleted vesicles were subjected to sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and
anti-Flag immunoblot analysis. For binding of recombinant proteins
to lipids on PIP strips (lipid^protein overlays), strips were blocked 90
min before adding the puri¢ed recombinant proteins at 0.5 Wg/ml in
blocking solution (10 mM Tris pH 7.5+150 mM NaCl+0.1% Tween-
20+3% fatty acid-free bovine serum albumin). Strips were then incu-
bated overnight at 4‡C, washed and Flag-tagged proteins visualized
by immunoblot with anti-Flag antibodies.
2.4. Cell culture, transfection and AlF34 treatment
HeLa cells were maintained as described [7] and transfected using
either lipofectin (Invitrogen) or the calcium phosphate method. For
AlF34 treatment, ARF6-transfected cells were incubated for 30 min
with complete medium plus 30 mM HEPES pH 7.4 and next for
another 30 min with the same solution to which 30 mM NaF and
50WM AlCl3 had been added.
2.5. Confocal microscopy
HeLa cells were processed for immuno£uorescence analysis as pre-
viously described [7]. Samples were observed under a Leica TCS-NT
confocal microscope. The di¡erent £uorophores were excited and im-
ages captured sequentially so as to avoid channel crosstalk. All images
displayed are optical sections.
3. Results
3.1. HERC1 is recruited to aluminum £uoride-induced actin
protrusions in HeLa cells
In order to analyze whether HERC1 might be recruited to
ARF6-dependent actin protrusions, HeLa cells were trans-
fected with plasmid pARF6-HA, encoding wild type ARF6
fused to a carboxyl-terminal hemagglutinin (HA) epitope, and
treated about 24^40 h later with the heterotrimeric G protein
activator AlF34 for 30 min. Cells were then ¢xed and pro-
cessed for immuno£uorescence microscopy. As previously de-
scribed [15], AlF34 treatment of ARF6-transfected HeLa cells
induced the assembly of surface protrusions to which both F-
actin and ARF6-HA (Fig. 1A) translocated. In much the
same manner, a subset of endogenous HERC1 also clearly
moved from its normal perinuclear localization to these pro-
trusive structures (Fig. 1A). These HERC1-containing struc-
tures did not form when HeLa cells were either not trans-
fected (data not shown) or transfected with ARF1 (Fig. 1B).
What is more, a dominant-negative mutant of ARF6 (ARF6-
T27N) also prevented HERC1 translocation upon AlF34 treat-
ment, thus proving the need for ARF6 activation in this pro-
cess (Fig. 1C, top). Finally, a constitutively active mutant of
ARF6 (ARF6-Q67L), which has previously been shown to
give rise to actin-containing protrusive structures at the plas-
ma membrane resembling those induced by AlF34 [15], did
indeed colocalize with HERC1 in these structures (Fig. 1C,
bottom).
3.2. HERC1 overexpression does not induce actin protrusions
in the absence of aluminum £uoride
Since HERC1 has been shown to catalyze guanine nucleo-
tide dissociation upon ARF and Rab family members [1], we
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thought that HERC1 might be involved in ARF6 activation
in this system. If this were true, HERC1 overexpression in the
absence of AlF34 should su⁄ce to evoke actin protrusion for-
mation, as it has already been seen for other ARF6-GEFs
such as ARNO and EFA6 [19,20]. In order to test this, we
cotransfected HeLa cells with both pARF6-HA and pJLR155,
a plasmid encoding a fusion protein between GFP and full-
length HERC1. Expression of GFP-HERC1 neither induced
protrusion assembly in the absence of AlF34 nor prevented
their appearance when this compound was added (Fig. 2,
bottom panels). At the same time, in a positive control where
both pARF6-HA and pARNO-Myc (C-terminal Myc epitope-
tagged ARNO) had been cotransfected, protrusions contain-
ing both actin and HERC1 formed without any need for
AlF34 (Fig. 2, top panels). These results most probably indi-
cate that HERC1 is not acting as an ARF6-GEF in this
system but that its recruitment to protrusions takes place
downstream of ARF6 activation.
3.3. The RLD1 domain of HERC1 binds phosphoinositides
It is becoming increasingly clear that many of the events
triggered as a result of ARF6 activation are mediated by the
Fig. 1. HERC1 recruitment onto actin protrusions. HeLa cells were transfected with a plasmid encoding ARF6-HA, treated with AlF34 , ¢xed
and processed for immunocytochemistry. A: AlF34 treatment resulted in the formation of membrane protrusions in which F-actin, detected us-
ing phalloidin-FITC, exogenous ARF6, detected using anti-HA antibodies, and endogenous HERC1, detected with speci¢c antibodies, are
present. B: Protrusions do not form in response to AlF34 when HeLa cells are transfected with a plasmid encoding ARF1-HA instead of
ARF6-HA. C: Transfection of dominant-negative ARF6-T27N blocks AlF34 -induced protrusion formation, while constitutively active ARF6-
Q67L induces HERC1-containing protrusions with no need of drug treatment. Scale bar 20 Wm.
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ability of this GTP-binding protein to elicit PI(4,5)P2 synthe-
sis. Indeed, PI(4,5)P2 has already been shown to be highly
enriched in ARF6-dependent actin protrusions [29] and thus
PI(4,5)P2-binding proteins are candidates to be recruited onto
these structures. In order to ¢nd out whether HERC1 is ca-
pable of associating to the aforementioned phospholipid,
binding assays were performed in which PI(4,5)P2-free or
PI(4,5)P2-containing liposomes were incubated together with
either the RLD1 or the RLD2 domain of HERC1, both pu-
ri¢ed from bacteria and possessing Flag epitopes in their car-
boxy-termini (Fig. 3A). As can be observed in Fig. 3B, RLD1-
Flag was pulled down when PI(4,5)P2-containing liposomes
were used. A smaller amount of RLD1-Flag was also found
with PI(4,5)P2-free ones, which suggests that RLD1-Flag may
either have a low, but detectable, a⁄nity for azolectin and/or
precipitate due to its intrinsic instability. Even if the latter is
true, though, this does not undermine the conclusion that
RLD1-Flag speci¢cally binds to PI(4,5)P2. On the other
hand, RLD2-Flag was not found associated with any of the
liposomes, which allows us to conclude that it is RLD1 and
not the Flag epitope that mediates binding to PI(4,5)P2. Next,
we wondered whether RLD1 could also bind other phospho-
inositides in addition to PI(4,5)P2. In order to answer this
question, we performed overlay assays on PIP strips. The
strips were blocked, incubated with either RLD1-Flag or
RLD2-Flag, washed and the bound RLD domains detected
with anti-Flag antibodies. As shown in Fig. 3C, HERC1’s
RLD1 has a⁄nity for several membrane phospholipids, in-
cluding all monophosphate phosphoinositides as well as
PI(3,5)P2, PI(4,5)P2 and phosphatidic acid. RLD2, on the
other hand, does not appear to associate with any of these
molecules. Finally, we studied whether HERC1-containing
protrusions were also enriched in PI(4,5)P2 (visualized by ex-
pressing a fusion protein of the pleckstrin homology domain
of PLCN1 and GFP) and the enzyme involved in its synthesis,
namely PI(4)P-5K. As expected, both PI(4,5)P2 and trans-
fected Myc-tagged PI(4)P-5KK were found in protrusions to-
gether with HERC1 (Fig. 3D). Taken together, these results
suggest that HERC1 may be pulled to ARF6-dependent mem-
brane protrusions as a result of the capability of its RLD1
domain to interact with phosphoinositides such as PI(4,5)P2.
4. Discussion
In the present study, we have shown that the giant protein
HERC1 undergoes recruitment onto actin-based membrane
Fig. 2. HERC1 recruitment takes place downstream of ARF6 activation. HeLa cells were cotransfected with wild type ARF6-HA and either
ARNO-Myc (positive control, top panels) or GFP-HERC1 (bottom panels). Cells were then treated, when appropriate, with AlF34 , ¢xed and
processed for immunocytochemical analysis. ARNO-Myc was detected with anti-Myc antibodies, F-actin with phalloidin-TRITC and HERC1
with speci¢c antibodies. Whereas ARNO induced HERC1-containing protrusions already in the absence of AlF34 (top), GFP-HERC1 was not
able to do so nor did it block protrusion assembly when AlF34 was added (bottom). Scale bars 20 Wm.
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Fig. 3. HERC1’s RLD1 domain binds to phosphoinositides. A: RLD1-Flag and RLD2-Flag were heterologously expressed in E. coli and puri-
¢ed by a⁄nity chromatography. Puri¢ed samples were run on an SDS^PAGE gel which was stained with Coomassie blue dye. B: Liposome^
protein complex formation assays were performed in which PI(4,5)P2-free or PI(4,5)P2-containing liposomes were incubated together with either
RLD1-Flag or RLD2-Flag. Liposomes were then pulled down by centrifugation and the amount of associated RLDs was analyzed by SDS^
PAGE followed by immunoblot with an anti-Flag antibody. C: PIP strips were incubated with recombinant Flag-tagged RLDs (0.5 Wg/ml)
overnight at 4‡C as detailed in Section 2. After washing, bound RLDs were visualized by immunoblotting with anti-Flag antibodies. (Abbrevia-
tions: LPA, lysophosphatidic acid; LPC, lysophosphocholine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; Sph(1)P, sphingosine-1-
phosphate; PA, phosphatidic acid; PS, phosphatidylserine). D: HERC1 colocalizes in AlF34 -induced protrusions with both PI(4,5)P2 and
PI(4)P-5K. HeLa cells were transfected with ARF6 and either PH-PLCN1-GFP to visualize PI(4,5)P2 or Myc-tagged PI(4)P-5K, which was de-
tected with anti-Myc antibodies. Cells were processed for immuno£uorescence microscopy as described in Section 2. Scale bars 20 Wm.
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protrusions formed in ARF6-overexpressing HeLa cells upon
addition of AlF34 . We have also shown that these HERC1-
enriched protrusions speci¢cally require ARF6 activation in
order to form and do not therefore arise as a result of some
non-speci¢c action of AlF34 drug treatment. In addition, we
have demonstrated that HERC1 is not involved in ARF6
activation and thus cannot be acting as an ARF6-GEF in
these cells, since otherwise its overexpression would give rise
to protrusions in the absence of AlF34 , as happens with bona
¢de ARF6-GEFs such as ARNO and EFA6 [19,20]. The op-
posite, i.e. that HERC1 may somehow help inactivate ARF6,
can likewise be ruled out by the observation that HERC1
overexpression does not prevent protrusions from forming
when AlF34 is present. HERC1 must therefore be recruited
to actin protrusions after ARF6 has already been activated.
On the other hand, we have described a previously unknown
physical interaction between the RLD1 domain of HERC1
and several membrane phospholipids. Among these, the stron-
gest interaction takes place with PI(4)P and PI(5)P, followed
by PI(3)P, PI(4,5)P2, PI(3,5)P2 and phosphatidic acid. Since
PI(4,5)P2 has been shown to be highly enriched in actin pro-
trusions [29], we think that HERC1’s RLD1 binding to
PI(4,5)P2 may account, at least partly, for the recruitment
of HERC1 onto these structures. In this regard, our immuno-
£uorescence studies clearly show that HERC1 colocalizes with
both PI(4,5)P2 and PI(4)P-5K in actin protrusions. Further-
more, preliminary data from our lab show that several
HERC1 constructs containing the RLD1 domain go to
AlF34 -induced protrusions. However, the interaction(s) driving
HERC1 translocation onto protrusions must still be pin-
pointed and several alternatives exist apart from the one
postulated above. These include among others HERC1 asso-
ciation with other PI(4,5)P2-binding proteins as well as
HERC1’s RLD1 binding to phosphatidic acid, the product
of phospholipase D, which, like PI(4)P-5K, has also been
shown to be activated by ARF6-GTP [32]. On the other
hand, binding of HERC1 to PI(4)P and PI(3)P may be of
greater signi¢cance in the Golgi apparatus and early endo-
somes, respectively, where these phosphoinositides have re-
cently been shown to perform important functions [33,34]
and where HERC1 is also known to be located ([1] and un-
published data).
Regardless of the mechanism whereby HERC1 moves to
these protrusions, the important issue concerning HERC1’s
function in these structures remains unsettled. At ¢rst glance,
HERC1 does not appear to have a direct role in the enhance-
ment of actin polymerization at the plasma membrane, since
its overexpression does not a¡ect protrusion formation (Fig.
2). A more appealing possibility comes from the fact that
HERC1’s multidomain structure makes it suitable to act as
a sca¡olding protein by interacting simultaneously with many
other proteins, thus bringing them together, in a way similar
to the manner in which the protein paxillin works [35]. If
HERC1 played such a structural role, it is conceivable that
its mere overexpression is not enough to induce great changes
in the cell cortex, since the signaling pathways involved in the
activation of protrusion formation would not necessarily be-
come activated. Yet another possibility is that HERC1 is in-
volved in macropinocytosis, a process which is strongly stimu-
lated at protrusive sites [17,36]. This would be in better
agreement with HERC1’s background in membrane tra⁄c
as well as with preliminary data from our lab showing
HERC1’s involvement in £uid-phase pinocytosis (F.R. Gar-
cia-Gonzalo and J.L. Rosa, data not shown). In summary,
our ¢ndings shed some more light to the issue of HERC1
function and open some new areas of research to be pursued
in the future.
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